Expression of biliary antigen and its clinical significance in hepatocellular carcinoma
- PMID: 10565259
- DOI: 10.3349/ymj.1999.40.5.472
Expression of biliary antigen and its clinical significance in hepatocellular carcinoma
Abstract
In order to classify the hepatocellular carcinomas (HCCs) which had diverse clinicopathologic characteristics, we divided HCCs into two groups according to the expression of biliary antigen on the basis of the hypothesis that the hepatocyte and biliary epithelial cell originate from the same precursor cell, and then we investigated the clinical and pathologic characteristics in the two groups. Forty HCC cases with no preoperative treatment and at least two-year follow-up data were selected among 202 cases of HCC files from 1991 to 1995. Expression of biliary antigen (AE1, cytokeratin 19), p53, AFP, and Ki-67 in the tumor tissue were assessed by immunohistochemistry. Positive cytokeratin 19 was noted in one case (2.5%); AE1 was detected in 40% of patients; p53 was overexpressed in 20% of patients; and AFP was detected in 45% of patients. No statistical difference between the biliary antigen positive group (16 cases) and the negative group (24 cases) were noted in terms of mean age, sex, presurgical serum AFP level, Child class, and tumor size. HBsAg positive rate was 66.7% for the biliary antigen (-) group and 93.8% for the biliary antigen (+) group with a statistically significant difference (p = 0.048). The number of cases for Edmonson-Steiner grade I/II and III/IV were 15 and 9 in the biliary antigen (-) group, and 4 and 12 in the biliary antigen (+) group, respectively, with a statistically significant difference (p = 0.024). The 1, 3 and 5-year disease-free survival rates were 69.7, 40.9 and 40.9% for the biliary antigen (-) group and 73.7, 39.1, 39.1% for the biliary antigen (+) group with no statistically significant difference. The 1, 3 and 5-year overall survival rates were 91.7, 73.8, 66.4% for the biliary antigen (-) group and 68.8, 34.4, 34.4% for the biliary antigen (+) group, with a significantly greater overall survival rate for the biliary antigen negative group (p = 0.045). Poor histopathological differentiation, a high HBsAg positive rate and poor overall survival rate were noted in the biliary antigen positive group and the differences were statistically significant. In conclusion, HCCs with positive biliary antigen, which originates from more primitive cells, is suggested to be more aggressive than HCCs with negative biliary antigen.
Similar articles
-
Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications.Am J Pathol. 1996 Oct;149(4):1167-75. Am J Pathol. 1996. PMID: 8863666 Free PMC article.
-
Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness.Hum Pathol. 2016 Apr;50:24-33. doi: 10.1016/j.humpath.2015.10.014. Epub 2015 Nov 4. Hum Pathol. 2016. PMID: 26997435
-
Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma.Am J Surg Pathol. 2007 May;31(5):783-91. doi: 10.1097/01.pas.0000213421.53750.0a. Am J Surg Pathol. 2007. PMID: 17460464
-
Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma.J Surg Oncol. 2004 Jan;85(1):48-54. doi: 10.1002/jso.20006. J Surg Oncol. 2004. PMID: 14696087
-
P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.Liver Int. 2007 Aug;27(6):772-81. doi: 10.1111/j.1478-3231.2007.01499.x. Liver Int. 2007. PMID: 17617120
Cited by
-
Hepatic progenitor cells in human liver tumor development.World J Gastroenterol. 2006 Oct 21;12(39):6261-5. doi: 10.3748/wjg.v12.i39.6261. World J Gastroenterol. 2006. PMID: 17072946 Free PMC article. Review.
-
From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms.Genome Med. 2012 Jan 31;4(1):8. doi: 10.1186/gm307. Genome Med. 2012. PMID: 22293089 Free PMC article.
-
Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.Yonsei Med J. 2005 Aug 31;46(4):519-25. doi: 10.3349/ymj.2005.46.4.519. Yonsei Med J. 2005. PMID: 16127777 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous